Impact of Implantable Cardioverter-Defibrillator, Amiodarone, and Placebo on the Mode of Death in Stable Patients With Heart Failure | Zendy

Douglas L. Packer | Zendy; Jordan M. Prutkin | Zendy; Anne S. Hellkamp | Zendy; L. Brent Mitchell | Zendy; Robert Bernstein | Zendy; Freda Wood | Zendy; John Boehmer | Zendy; Mark D. Carlson | Zendy; Robert P. Frantz | Zendy; Steve E. McNulty | Zendy; Joseph G. Rogers | Zendy; Jill Anderson | Zendy; George Johnson | Zendy; Mary Norine Walsh | Zendy; Jeanne E. Poole | Zendy; Daniel B. Mark | Zendy; Kerry L. Lee | Zendy; Gust H. Bardy | Zendy

Open Access

Impact of Implantable Cardioverter-Defibrillator, Amiodarone, and Placebo on the Mode of Death in Stable Patients With Heart Failure

Author(s) -

Douglas L. Packer,

Jordan M. Prutkin,

Anne S. Hellkamp,

L. Brent Mitchell,

Robert Bernstein,

Freda Wood,

John Boehmer,

Mark D. Carlson,

Robert P. Frantz,

Steve E. McNulty,

Joseph G. Rogers,

Jill Anderson,

George Johnson,

Mary Norine Walsh,

Jeanne E. Poole,

Daniel B. Mark,

Kerry L. Lee,

Gust H. Bardy

Publication year - 2009

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.109.853689

Subject(s) - medicine , implantable cardioverter defibrillator , amiodarone , heart failure , cardiology , placebo , atrial fibrillation , alternative medicine , pathology

The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) demonstrated that implantable cardioverter-defibrillator (ICD) therapy reduces all-cause mortality in patients with New York Heart Association class II/III heart failure and a left ventricular ejection fraction < or =35% on optimal medical therapy. Whether ICD therapy reduced sudden death caused by ventricular tachyarrhythmias without affecting heart failure deaths in this population is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research